Brought to you by 
Celgene gets rights to Epizyme’s personalized cancer therapeutics
25 May 2021
Executive Summary
Celgene Corp. will work with epigenetics company Epizyme Inc. to discover, develop, and sell new personalized cancer therapeutics based on Epizyme’s work with histone methyltransferase (HMT) inhibitors for genetically defined cancers.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene gets rights to Epizyme’s personalized cancer therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice